Rasio cepet Eliem Therapeutics Inc. (ELYM)

This price chart illustrates the price action of Eliem Therapeutics (ELYM), whose potential is tied to successes in the therapy of depression and pain syndromes. Developments in ion channels and expert support create a foundation for future blockbusters. Meanwhile, lengthy testing cycles and patents guarantee an inflow of funds. However, the merger with Tenet wiped out the cash flow, and the company currently relies on external capital, reaching the level of 60.61.

Assessing a company's ability to instantaneously settle its obligations is critical for asset stress testing. Eliem Therapeutics (ELYM), as a biotech startup with a minimal operational footprint, maintains no significant inventory. The quick liquidity statistics here reflect a balance solely between cash, accounts receivable, and current liabilities. The stability of this metric confirms the business's financial resilience during a period of costly clinical trials.